Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Tumor Lysis Syndrome 1Hematologic Neoplasms 1

Interventions

pembrolizumab 77Cyclophosphamide 50Cisplatin 47Nivolumab 37Paclitaxel 34Radiotherapy 33Carboplatin 32Gemcitabine 30Docetaxel 27Dexamethasone 24atezolizumab 23Doxorubicin 21Bevacizumab 21Etoposide 20Blood Specimen Collection 20Magnetic Resonance Spectroscopy 19Vincristine 18Radiosurgery 18Leucovorin 18Lenalidomide 18Fluorouracil 18fludarabine 17Rituximab 17Surveys and Questionnaires 16Oxaliplatin 16Ipilimumab 16Cytarabine 16palbociclib 15Radiation 15Letrozole 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Amides × 90 days × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡